Please enable JavaScript or talk to your local administrator to get JavaScript enabled.
Skip filters
Skip facets
  • 17

  • 6

  • 3

  • 3

  • 2

  • 2

  • 1

  • 1

  • 1

  • 1

Funder Group
Research Organization
FOR (ANZSRC) Category
RCDC Category
Country of Funder
Start Year
Active Year
Similar Projects for



Funder: European Commission

Funding period
EUR 50 K
USD 56 K
Funding amount
Bladder cancer is the 5th most common cancer in Europe, with almost 200,000 new cases and 65,000 deaths estimated in 2018. People at high risk for developing this disease include smokers, former smokers, people living in polluted areas, and workers exposed to certain chemicals. The risk of dying from bladder cancer depends on the time of diagnosis and the tumour’s grade: the 5-year survival rate is >95% in early stage cancer, but it drops to <5% in late stage tumours. Besides increased survival, the identification of bladder cancer at its early stages is also associated with easier, less invasive, and cheaper treatment.
Given the importance of early detection and the high incidence of bladder cancer, screening programs for this disease are needed. However, there is no screening tool currently available for bladder cancer. As a solution, VitaDX is developing VisioCyt Screening: a software that combines artificial intelligence algorithms with standard cytology analysis to predict with high accuracy the presence of bladder cancer in patients, even before symptoms appear. Being a software that analyses images obtained through regular clinical procedures, VisioCyt Screening can be readily implemented in centralized labs, resulting in a fast, easy-to-use, reproducible, automated, and high-throughput solution at a low price.
VisioCyt Screening can be classified as an in-vitro diagnostic (IVD) medical device. The global IVD market was estimated at €58 billion in 2018, and is expected to reach €75.2 billion by 2023, with a CAGR rate of 5.2%. In this market, centralized laboratories, which perform large numbers of analyses in few locations and are equipped with the automated systems required by the VisioCyt solution, represent the most relevant target users and customers for VitaDX.
VitaDX is a French SME that combines a strong scientific and clinical background with software and image processing skills and business expertise to develop new diagnostic solutions for cancer.

USD 30.6 M
Aggregated funding amount
USD 926 K
Average funding amount
Project list item
Alpha1H: A Unique Bladder Cancer Therapeutic, Acting with Great Precision

European Commission

USD 2,452,885
2020 - 2022
Project list item
Roles of epigenetic regulators in bladder cancer progression

University of California - Cancer Research Coordinating Committee to Zhu Wang

USD 74,960
2020 - 2020
Project list item
A revolutionary shape memory alloy-based disposable device for bladder cancer removal

European Commission

USD 55,967
2019 - 2019
Project list item
Improved detection of bladder cancer recurrence using a biophysical biomarker

National Cancer Institute to MICHAEL D HENRY

USD 301,860
2017 - 2020
Project list item
(PQ3) Immune epigenetic biomarkers of bladder cancer outcomes

National Cancer Institute to BROCK CLARKE CHRISTENSEN

USD 1,829,226
2017 - 2022
Project list item
High resolution imaging for early and better detection of bladder cancer

Cancer Prevention and Research Institute of Texas to Rebecca R Richards-Kortum

USD 873,765
2015 -
Project list item
Precision Medicine in Platinum-Treated Lethal Bladder Cancer

Congressionally Directed Medical Research Programs to Eliezer M Van allen

USD 346,210
2015 - 2016
Project list item
Precision Medicine in Platinum-Treated Lethal Bladder Cancer

Congressionally Directed Medical Research Programs to Jonathan Rosenberg

USD 788,605
2015 - 2016
Project list item
Precision Medicine in Platinum-Treated Lethal Bladder Cancer

Congressionally Directed Medical Research Programs to David Mcconkey

USD 411,266
2015 - 2016
Project list item
Visible Light-Controlled Combination Strategy for Treating Nonmuscle Invasive Bladder Cancers

Congressionally Directed Medical Research Programs to Kelly Standifer

USD 592,000
2015 - 2016
Project list item
Synergistic Immuno-Photo-Nanotherapy for Bladder Cancer

Congressionally Directed Medical Research Programs to Brant A. Inman

USD 624,398
2015 - 2016
Project list item
bLadder cAncer URine cEll aNalysis

European Commission

USD 3,534,487
2015 - 2018
Project list item
Early Detection of Bladder Cancer Using a Waveguide Array Biosensor

National Cancer Institute to SHELLY MECHERY

USD 149,999
2014 - 2015
Project list item
Detection of COX-2-expressing bladder cancer by fluorocoxib A

National Cancer Institute to MARIA CEKANOVA

USD 414,939
2014 - 2018
Project list item
Biomarkers for Staging and Treatment Response Monitoring of Bladder Cancer

National Cancer Institute to LUBOMIR M HADJIYSKI

USD 2,153,403
2014 - 2019
Project list item
Establishing a biological network strategy for personalizing prognosis in non-muscle invasive bladder cancer

Canadian Cancer Society to Jeffrey Wrana, Azar Azad, Benjamin Blencowe, Girish Kulkarni, Quaid Morris, Theodorus Van der kwast, Alexandre Zlotta

USD 996,076
2014 - 2019
Project list item
Molecular and Genetic Studies of Bladder Tumorigenesis

United States Department of Veterans Affairs to XUE-RU WU

2013 - 2022
load more...